Draft:Sunshine Biopharma

GT Biopharma to Present at Raymond James Human Health Innovation Conference

Retrieved on: 
Wednesday, June 16, 2021
Draft:Sunshine Biopharma, Sutro Biopharma

BEVERLY HILLS,Calif., June 16, 2021 /PRNewswire/ --GT Biopharma, Inc. ("GT Biopharma" or the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager (TriKE) protein biologic technology platform, today announced that it will provide a corporate update at the upcoming Raymond James Human Health Innovation Conference on Tuesday, June 22, 2021 at 11:20 AM ET.

Key Points: 
  • BEVERLY HILLS,Calif., June 16, 2021 /PRNewswire/ --GT Biopharma, Inc. ("GT Biopharma" or the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager (TriKE) protein biologic technology platform, today announced that it will provide a corporate update at the upcoming Raymond James Human Health Innovation Conference on Tuesday, June 22, 2021 at 11:20 AM ET.
  • A live webcast of the event will be available by visiting "Presentations" page in the Investors section of GT Biopharma's website at www.gtbiopharma.com/news-media/presentations .
  • GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE NK cell engager platform.
  • GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology.

Enteris BioPharma to Host Webinar on High Potency Active Pharmaceutical Ingredients in Oral Drug Development

Retrieved on: 
Tuesday, June 15, 2021
Consalvo, Drug delivery, Draft:Sunshine Biopharma

ET, and will be co-hosted by Josh Stephens, Enteris' Sales Manager, Pharmaceutical Drug Delivery, and Angelo Consalvo, Enteris' Director of Manufacturing.

Key Points: 
  • ET, and will be co-hosted by Josh Stephens, Enteris' Sales Manager, Pharmaceutical Drug Delivery, and Angelo Consalvo, Enteris' Director of Manufacturing.
  • Details of the webinar are as follows:
    Mr. Consalvo has more than 34 years of biopharma experience in process development and manufacturing.
  • The technologies have been the subject of numerous feasibility studies and active development programs, several of which are in clinical development.
  • For more information on Enteris BioPharma and its proprietary drug delivery technologies, please visit http://www.EnterisBioPharma.com .

Ascendis Pharma A/S Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ hGH (Lonapegsomatropin) for Pediatric Growth Hormone Deficiency

Retrieved on: 
Friday, June 11, 2021
Draft:Sunshine Biopharma, NIFTY 50, Draft:Medison Pharma

Accordingly, the FDA has extended the Prescription Drug User Fee Act goal date by three months, to September 25, 2021.

Key Points: 
  • Accordingly, the FDA has extended the Prescription Drug User Fee Act goal date by three months, to September 25, 2021.
  • Ascendis Pharmais applying its innovative platform technology to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients lives.
  • Ascendis Pharma currently has a pipeline of three independent endocrinology rare disease product candidates and one oncology product candidate in clinical development.
  • Ascendis,Ascendis Pharma, theAscendis Pharmalogo, the company logo and TransCon are trademarks owned by theAscendis Pharma Group.

Pharmaceutical Executive® Unveils the 21st Annual Pharma 50

Retrieved on: 
Thursday, June 10, 2021
Health sciences, Pharmaceutical sciences, Pharmaceutical industry, Pharmacology, Pharmacy, Health care, Pharmaceuticals policy, Draft:Sunshine Biopharma

Pharmaceutical Executive based rankings of the top 50 global biopharma leaders on companies' prescription drug sales.

Key Points: 
  • Pharmaceutical Executive based rankings of the top 50 global biopharma leaders on companies' prescription drug sales.
  • "With the end of the COVID-19 pandemic in sight, the Pharmaceutical Executive Pharma 50 list demonstrates the top sales performers that played a part in combating the public health crisis the industry has been facing," said Mike Hennessy Jr., president and CEO of MJH Life Sciences, parent company of Pharmaceutical Executive.
  • In addition to paying close attention to connected current trends, Pharmaceutical Executive based its rankings of the top 50 global biopharma leaders on the companies' full-year prescription drug sales in 2020.
  • Pharmaceutical Executive is a multimedia platform that offers news, opinions, analysis, features and executive profiles.

Sunshine Biopharma Mice Study for COVID-19 Treatment Progressing as Planned

Retrieved on: 
Wednesday, June 9, 2021
Protease inhibitor, Antiviral drugs, Draft:Sunshine Biopharma, Carbamates, Organofluorides, HIV protease inhibitors

The study is assessing the efficacy of two protease inhibitors in preventing transgenic mice challenged with SARS-CoV-2 from progressing to illness and death.

Key Points: 
  • The study is assessing the efficacy of two protease inhibitors in preventing transgenic mice challenged with SARS-CoV-2 from progressing to illness and death.
  • Sunshine Biopharmas protease inhibitor treatment is anticipated to be orally available making it possible for the treatment to be in tablet form which can be taken at home.
  • We are moving the project forward as fast as possible, albeit within the constraints of science, said Dr. Steve Slilaty, CEO of Sunshine Biopharma.
  • In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound.

AzurRx BioPharma Doses First Patient In Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

Retrieved on: 
Monday, June 7, 2021
Anthelmintics, Chloroarenes, Niclosamide, Nitrobenzenes, Pesticides, Salicylanilides, Chemical substances, Chemistry, Draft:Sunshine Biopharma

FW-1022 is a proprietary oral tablet formulation of micronized niclosamide developed for the treatment of COVID-19-related GI infections.

Key Points: 
  • FW-1022 is a proprietary oral tablet formulation of micronized niclosamide developed for the treatment of COVID-19-related GI infections.
  • Dosing the first patient in the RESERVOIR clinical trial marks a significant milestone for AzurRx and the development of niclosamide as a potential treatment for COVID-19-related GI infections, said James Sapirstein, Chief Executive Officer of AzurRx BioPharma.
  • The RESERVOIR clinical trial is designed as a two-part, two-arm, placebo-controlled Phase 2 study.
  • AzurRx BioPharma, Inc. (NASDAQ: AZRX) is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases.

POINT Biopharma Receives U.S. Nuclear Regulatory Commission Materials License for Indiana Facility

Retrieved on: 
Tuesday, June 1, 2021
Biotechnology, Pharmaceutical, Health, Indianapolis, National Road, Cities in the United States, Political divisions of the United States, Draft:Sunshine Biopharma, Therapeutics Acquisition Corp, d/b/a Research Alliance Corp. I, RA Capital Management, POINT Biopharma, THERAPEUTICS ACQUISITION CORP, D/B/A RESEARCH ALLIANCE CORP. I, RA CAPITAL MANAGEMENT, POINT BIOPHARMA

POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients, announced today that the U.S. Nuclear Regulatory Commission (NRC) has issued a Materials License for its new production facility located in Indianapolis, Indiana.

Key Points: 
  • POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients, announced today that the U.S. Nuclear Regulatory Commission (NRC) has issued a Materials License for its new production facility located in Indianapolis, Indiana.
  • The completion of our Indianapolis facility and scope of this Materials License will enable POINT to quickly bring its drug manufacturing operations online, said Todd Hockemeyer, EVP, US Manufacturing Operations at POINT Biopharma.
  • I am proud of the many accomplishments Todd and his team in Indiana have achieved, added Joe McCann, CEO of POINT Biopharma.
  • POINT expects the Indianapolis facility will begin to provide supply for its Phase 3 clinical trial targeting metastatic castration resistant prostate cancer later this year.

Eucure Biopharma to Present Findings From Anti-CD40 and Anti-CTLA-4 mAb Clinical Trials at the 2021 ASCO Meeting

Retrieved on: 
Tuesday, June 1, 2021
Draft:Sunshine Biopharma

BEIJING and BOSTON, June 1, 2021 /PRNewswire/ -- Eucure Biopharma will present findings from two Phase I clinical trials at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, held from June 4th to 8th.

Key Points: 
  • BEIJING and BOSTON, June 1, 2021 /PRNewswire/ -- Eucure Biopharma will present findings from two Phase I clinical trials at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, held from June 4th to 8th.
  • As of December 31, 2020, no DLT or severe AE were observed at 4 dose levels (ranging from 0.05 to 1 mg/kg).
  • Eucure Biopharma is a biopharmaceutical company focused on the development of innovative immunotherapies to meet clinical needs of patients around the world.
  • Relying on a strong clinical development team with extensive experience, the company has established a product pipeline for more than 10 targets.

Connect Biopharma to Participate at the Jefferies Virtual Healthcare Conference

Retrieved on: 
Wednesday, May 26, 2021
Life sciences, Biotechnology, Health sciences, Biopharmaceutical, Pharmaceutical industry, Pharmacy, Draft:Sunshine Biopharma, Arbutus Biopharma

SAN DIEGO and TAICANG, SUZHOU, China, May 26, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the Company), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that Dr. Zheng Wei, Co-Founder & CEO of Connect Biopharma, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 10:00 am ET.

Key Points: 
  • SAN DIEGO and TAICANG, SUZHOU, China, May 26, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the Company), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that Dr. Zheng Wei, Co-Founder & CEO of Connect Biopharma, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 10:00 am ET.
  • A live webcast of this fireside chat will be available on the Companys Investor Relations page accessible here: https://investors.connectbiopharm.com/ .
  • Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients living with chronic inflammatory diseases through the development of therapies derived from our T cell-driven research.
  • For additional information about Connect Biopharma, please visit our website at www.connectbiopharm.com .

Antengene Appoints Kathryn Gregory as Vice President and Head of Corporate Business Development

Retrieved on: 
Tuesday, May 25, 2021
Chief business officer, Corporate governance, Leadership, Business, Draft:Sunshine Biopharma, Articles, Nuvelo

In this role, Kathryn will be responsible for leading external business development including in/out-licensing, co-development/commercialization, mergers and acquisitions, and other collaboration agreements supporting Antengene's objectives.

Key Points: 
  • In this role, Kathryn will be responsible for leading external business development including in/out-licensing, co-development/commercialization, mergers and acquisitions, and other collaboration agreements supporting Antengene's objectives.
  • Prior to joining Antengene, Kathryn was the Chief Business Officer at Aileron Therapeutics.
  • Previously, she was the President of KG BioPharma Consulting LLC, a strategic advisory company, where she assisted biopharma companies in a range of corporate strategy and business development activities.
  • I believe her experience will make significant contributions to our business development initiatives," said Mr. John F. Chin, Chief Business Officer of Antengene.